StockData
Protalix BioTherapeutics, Inc. logo

Protalix BioTherapeutics, Inc. (PLX) stock

PLXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 16/3044% below fair value
$2.88−0.15 (-4.95%)

Close on Nov 17, 2026Market cap $232.05MP/E 12.5Yield –

Protalix BioTherapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Protalix BioTherapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was $9.92M. For fiscal 2025 it was -$11.99M, down 238.3% from the year before. The highest annual figure on record is $44.45M in fiscal 2009.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$11.99M-238.3%
FY2024Dec 31, 2024$8.67M–
FY2023Dec 31, 2023-$1.32M–
FY2022Dec 31, 2022-$25.00M–
FY2021Dec 31, 2021-$10.29M–
FY2020Dec 31, 2020-$26.11M–
FY2019Dec 31, 2019-$19.36M–
FY2018Dec 31, 2018-$7.74M–
FY2017Dec 31, 2017-$9.99M–
FY2016Dec 31, 2016-$32.10M–
FY2015Dec 31, 2015-$24.28M–
FY2014Dec 31, 2014-$29.28M–
FY2013Dec 31, 2013-$30.65M-4927.2%
FY2012Dec 31, 2012$635.00K–
FY2011Dec 31, 2011-$23.57M–
FY2010Dec 31, 2010-$38.46M-186.5%
FY2009Dec 31, 2009$44.45M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$10.40M–
Q1 FY2026Mar 31, 2026$22.03M–
Q4 FY2025Dec 31, 2025$2.03M-49.1%
Q3 FY2025Sep 30, 2025-$3.73M-190.9%
Q2 FY2025Jun 30, 2025-$5.23M–
Q1 FY2025Mar 31, 2025-$5.06M-220.8%
Q4 FY2024Dec 31, 2024$3.99M+11.0%
Q3 FY2024Sep 30, 2024$4.11M–
Q2 FY2024Jun 30, 2024-$3.61M-172.6%
Q1 FY2024Mar 31, 2024$4.19M–
Q4 FY2023Dec 31, 2023$3.60M–
Q3 FY2023Sep 30, 2023-$6.89M–
Q2 FY2023Jun 30, 2023$4.97M–
Q1 FY2023Mar 31, 2023-$3.00M–
Q4 FY2022Dec 31, 2022-$2.61M–
Q3 FY2022Sep 30, 2022-$9.20M–
Q2 FY2022Jun 30, 2022-$7.36M-212.9%
Q1 FY2022Mar 31, 2022-$5.83M–
Q4 FY2021Dec 31, 2021-$5.09M–
Q3 FY2021Sep 30, 2021-$1.88M–
Q2 FY2021Jun 30, 2021$6.52M–
Q1 FY2021Mar 31, 2021-$9.83M–
Q4 FY2020Dec 31, 2020-$7.55M–
Q1 FY2020Mar 31, 2020-$7.12M–
Q4 FY2019Dec 31, 2019-$3.69M–
Q3 FY2019Sep 30, 2019-$3.23M-123.6%
Q2 FY2019Jun 30, 2019-$5.17M–
Q1 FY2019Mar 31, 2019-$7.28M–
Q4 FY2018Dec 31, 2018-$4.00M-122.8%
Q3 FY2018Sep 30, 2018$13.64M–
Q2 FY2018Jun 30, 2018-$7.96M–
Q1 FY2018Mar 31, 2018-$9.41M–
Q4 FY2017Dec 31, 2017$17.59M–
Q3 FY2017Sep 30, 2017-$10.54M–
Q2 FY2017Jun 30, 2017-$8.62M–
Q1 FY2017Mar 31, 2017-$8.43M–
Q4 FY2016Dec 31, 2016-$7.34M–
Q3 FY2016Sep 30, 2016-$3.44M–
Q2 FY2016Jun 30, 2016-$11.69M–

More Protalix BioTherapeutics figures

See a number that looks wrong?